Malignant rhabdoid tumor was originally described in the kidney as a variant of Wilms' tumor in 1978 by Beckwith and Palmer [1] . Extrarenal forms of this tumor are very rare but have been described in a variety of sites including soft tissues, paraspinal and paratesticular areas, the central nervous system, colon, tongue, prostate, liver, skin, thymus, heart, pelvis, uterus, and vulva. Only 13 vulvar cases have been reported thus far in the English literature. We are reporting the 14 th case and a review of the clinical features, management and prognosis of all cases.
A 51-year-old G4P3, postmenopausal woman presented to our Obstetrics and Gynecology Clinic, Erciyes University Faculty of Medicine, Kayseri, Turkey with a painless vulvar mass measuring 3 cm that was situated on the left labium major adjacent to the anterior comissura. The lesion first appeared 2 months previously and was locally excised by a gynecologist at a secondary care center with the presumed diagnosis of lipoma. The histopathological examination revealed an extrarenal rhabdoid tumor (ERT). At the time of referral to our center, 20 days after the excision, a recurrent tumor measuring 4 cm, which was painless, with irregular border and arising from the excision site was detected (Figure 1 ). On transvaginal ultrasonography, the uterus, endometrial thickness, and both ovaries were normal. A positron emission tomography/ computer tomography with 18-F-fludeoxyglucose (18-F-FDG PET/CT) was performed for metastases screening. The 18-F-FDG PET/CT detected a soft-tissue lesion showing hypermetabolic activity at the left labium major, measuring 39 mm Â 37 mm with irregular borders. The 18-F-FDG PET/CT image showed no lesion suspicious for metastasis. A wide local excision was performed with 1 cm surgical margin and pathologic examination confirmed ERT with negative margins.
Microscopically, tumor cells make a row of diffuse layers and prominent pleomorphism and atypia are remarkable. The tumor was composed of large polygonal cells, with extended basophilic cytoplasm. Nuclei were vesicular with distinctive nucleolus. Immunohistochemically, the neoplastic cells were diffusely positive for vimentin, CD 99, and Fli-1 and focally positive for pankeratin and epithelial membrane antigen. However, neoplastic cells were negative for cytokeratin 5/6, P63, human melanoma black monoclonal antibody 45, CD 34, desmin, S-100, actin, melan A, myoglobin, Wilms tumor-1, neuron-specific enolase, and synaptaophycin, which was consistent with the diagnosis of highgrade malignant rhabdoid tumor (Figure 2 ).
On complete healing of the operative wound, she was referred to the Radiation Oncology Department, Erciyes University Faculty of Medicine for adjuvant radiotherapy in view of aggressive histology, grade, and size (> 3 cm). She was treated with external beam radiotherapy of 60 Gy over a period of 4 weeks (5 d/wk) to prevent local recurrence. At 12 months from her initial diagnosis, she is alive without evidence of recurrent or metastatic disease.
Vulvar carcinoma is a very rare neoplasm that accounts for about 4% of all gynecological cancers and typically affects women in the 6 th decade and 7 th decade of their lives. The vast majority of vulvar cancers (~90%) are squamous cell carcinoma. Other cell types that are found less frequently are malignant melanoma, anaplastic carcinomas, adenocarcinoma of the Bartholin glands, and sarcomas [2] . ERT of the vulva is a rare but very aggressive neoplasm. Only 13 cases have been reported thus far in the English literature and six of those reported to date, died within a year of diagnosis ( Table 1) .
The majority of reported cases of ERTs of the vulva had a history of rapidly growing, painless mass on the labium major (8 of 13 cases: 3 right, 5 left). Other reported sites are the vulva (2 cases: 1 right, 1 left), clitoris (1 case), mons pubis (1 case), and one case at the mons pubis adjacent to the labium major as in our case. In contrast to squamous cell carcinoma of the vulva, most of the reported ERT cases were noted in young patients. The mean age of ERT patients was 38.5 ± 12.1 years (range, 19e63 years; Table 1 ).
The diagnosis of ERT is based on histopathology. Pathological evaluation with light microscopy and immunohistochemistry is the gold standard for differential diagnosis. It is important and difficult to differentiate ERT from epitheloid sarcoma, which is a rare soft tissue malignancy of mesenchymal origin, because of nonstandard immunohistologic criteria [3] . Broadly, these tumors express EMA, vimentin, and cytokeratins. They do not express desmin [4] . Exclusion of malign melanoma can be done with positive S100 and HMB stains, which should be negative in ERT. Additionally, it is useful to perform dysadherin expression assay, positive in epitheloid tumors, to differentiate ERT and epitheloid tumors [5] .
There is no consensus on the treatment of vulvar ERT. Because of the aggressive pattern and tendency for the early metastasis of these tumors, it may be useful to make PET-CT before treatment. However, the role of PET-CT in the management of these cases is yet to be determined. A radical resection either alone or in combination with inguinal lymph node dissection has been performed in most of the reported cases (9 cases with lymph node dissection, 4 cases local excision, and 1 case unknown). Although most of the cases were treated with local excision plus lymph node dissection, the accuracy of this process is unclear because of the negative histology of these nodes [6] . It is well known that vulvar sarcomas, unlike carcinomas, rarely spread via the lymphatic route. Because of this, lymph node dissection may lead to additional morbidity and delay in starting adjuvant therapy. Nevertheless, Chen et al [7] reported a case of ERT with lymphatic involvement. Sentinel lymph node detection, which is a less invasive method for evaluating lymphatic involvement, may be a good alternative in these cases. Perrone et al [8] and Brand et al [3] performed only surgery with or without lymph node dissection in four cases and all of them recurred rapidly. In two cases reported by Matias et al [9] and Igarashi et al [10] , initially local excision and adjuvant chemotherapy were performed. One of them died 9 months after diagnosis and the other was alive 8 months after the initial treatment [9, 10] . Two of 13 patients were treated with surgery plus chemoradiotherapy. After 4 months, one of them died with mediastinal and lymphatic metastases. The other patient died 8 months after initial treatment with lung metastases. Chen et al [7] performed surgery plus a combination of metronomic chemotherapy with paclitaxel and the antiangiogenic agent thalidomide. They recommended pelviceinguinal radiotherapy but the patient refused [7] . Together with the present case, four patients were treated with surgery plus radiotherapy and no recurrence was detected.
The role of adjuvant chemotherapy and radiotherapy after local excision is controversial in the treatment of ERT. Adjuvant chemotherapy has been used in five of the 13 patients and four of these five patients died within months. Gururangan et al [11] used multiple-agent chemotherapy in extracranial rhabdoid tumors and reported partial response. Ulutin et al [12] recommended postoperative adjuvant radiotherapy for patients with close surgical margins, with residual tumor, or with high-grade tumors. Together with our patient, six of all the cases previously reported have been treated with adjuvant radiotherapy. Because of aggressive histology, high grade, and gross tumor size, we preferred to combine surgery with adjuvant radiotherapy for local control. However, early local recurrence has been reported in a case with ERT despite combined surgery plus adjuvant radiotherapy [13] .
The reported median survival for patients with ERT is relatively short. Six of the 13 patients treated as ERT of the vulva died within a year of diagnosis. One of the Perrone et al's [8] patients died 138 months after diagnosis. Given the paucity of data, accurate estimation of survival in these patients is difficult, and larger series need to be reported.
In summary, ERT of the vulva is a very rare and aggressive tumor. Wide local excision of the primary and recurrent tumor is the treatment of choice. Adjuvant radiotherapy and chemotherapy do not appear to be effective in treating local and metastatic tumor. To determine a standard and effective treatment for ERT, we need larger series to accumulate data. Therefore, clinicians are recommended to present their individual cases for the establishment of guidelines for the treatment of ERT. 
